Table 3.

Summary of definitions and follow-up recommendations

1. Definitions

Residual/persistent disease: “presence of any radiological enhancement at 3 months radiological follow-up”

Radiological recurrence: “a new (after a period of non-enhancement) enhancing or growing lesion, inside or in the margin of the ablated zone”

2. Multidisciplinary composition of follow-up team

At least 1 urologist, 1 pathologist and 1 radiologist (experienced in post-ablation imaging)

3. Follow-up schedules

Follow-up interval:

Minimum FU period of 5 years, preferably extended to 10 years

First FU imaging at 3 months post-treatment

A minimum of two imaging studies in the first year

Biannual imaging in the second year

Annual imaging from the third year onwards

Strongly advised not to skip on the minimum recommended number of imaging studies

Imaging modalities

First option 3-phase CT scan (non-enhanced, arterial and nephrographic/cortico-medular), slice thickness ≤3 mm, IVP phase (delayed phase) advised if suspicion of urinary tract involvement or hydronephrosis

Second option MRI with multiparametric protocol including at least: T1, T2, DWI, DCE

In case of CKD 4/5 non-contrast-enhanced MRI or CEUS

Follow-up of metastasis

Annual examination for pulmonary metastasis, using CT thorax

Besides chest and abdomen, no other routine imaging for distant metastasis

4. Biopsy

Only in case of suspicion of residual disease/persistence or recurrence

5. Risk-adapted follow-up

Stage and grade are main determinants